ABF Ingredients consolidates health units into Biotexia brand

ABF Ingredients (ABFI) has announced a major structural reorganisation of its health and nutrition portfolio, merging three of its core businesses — ABbiotek Health, Fytexia, and Anzchem — into a single, unified entity called Biotexia.

This consolidation marks the end of these entities operating as independent brands, creating a more integrated partner for the global nutraceutical and functional food industries.

The rationale behind the merger is to simplify the company’s interface for customers who increasingly require multi-ingredient, science-backed solutions rather than isolated components. By combining these specialised businesses, ABF Ingredients aims to remove the historical silos between microbial fermentation expertise, botanical extraction, and regional distribution.

“The creation of Biotexia is a logical step in our strategic evolution,” said Laurent Hubert, CEO of Biotexia. “By uniting our teams, we are not just combining our portfolios; we are creating a more cohesive platform that allows us to better support our customers’ innovation pipelines, from the initial clinical research phase through to final product development.”

Strategic ambitions for the new brand are centred on high-growth wellness sectors, including digestive, immune, metabolic, brain, and women’s health. According to the company, the merger will accelerate the commercialisation of its proprietary ingredients, such as specialised propolis extracts and microbiome-modulating solutions, by pooling research and development resources.

“Our goal is to bridge the gap between pharmaceutical-grade efficacy and the evolving needs of the food and beverage industry,” Hubert added. “Today’s consumers are looking for health benefits that fit seamlessly into their daily lives, moving away from pills toward functional formats like powders, bars, and fortified drinks. Biotexia is now uniquely positioned to provide the stable, clinically-supported ingredients that make those products possible.”

This unified R&D approach is also designed to streamline the production of robust clinical dossiers, which are increasingly critical for navigating global regulatory requirements. By centralising its capabilities in France, Spain, Italy, and the Netherlands, Biotexia intends to enhance its global supply chain while pursuing aggressive growth in the Asia-Pacific region.

The transition to the Biotexia brand is currently underway across all international markets, with the company expecting the full integration of its marketing and product lines to be completed by the middle of 2026.